Synexus Acquires ClinPharm

December 7, 2009

Synexus has agreed to acquire Leipzig based ClinPharm and will complete the acquisition in January 2010. This deal will increase the number of Synexus’ Dedicated Research Centres to 26 in nine countries, strengthening its European reach.

Synexus is a multi-national company focused on the recruitment and running of clinical trials at its own Dedicated Research Centres. While it has a network of research centres in Central and Eastern Europe, this acquisition will add eight research centres in Germany.  It will strengthen Synexus’ Central and Eastern Europe portfolio of centres in Poland, Hungary and Bulgaria with additional sites in Austria and Ukraine. Synexus now has research centres in Western, Central and Eastern Europe, South Africa and Asia.

The ClinPharm acquisition will increase Synexus’ total patient population reach to over 30 million patients; an increase of 50 per cent globally and 100 per cent across Europe. ClinPharm also brings considerable additional therapy area experience to Synexus.

"In order to keep pace with the market’s demands it is necessary for us to increase our infrastructure and patient reach. ClinPharm provided the ideal opportunity as they have considerable presence in Western, Central and Eastern Europe and also understand the way we work,” said Synexus Chief Executive Michael Fort.

The deal will be finalised in January 2010 after ClinPharm’s year end. ClinPharm’s founding CEO, Hans-Detlev Stahl MD, Ph.D. (Melb). F.R.A.C.P joins Synexus as European Medical Director.

“It was a natural fit to team up with Synexus.  We know each other very well and our geographic coverage is totally complementary. Together we are much stronger and I look forward to helping the new company with further expansion which delivers real benefits to our clients in pharma,” said Dr Stahl. 

Related Content:

News